• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.

作者信息

Hardt W, Schmidt-Gollwitzer M

出版信息

Clin Endocrinol (Oxf). 1983 Nov;19(5):613-7. doi: 10.1111/j.1365-2265.1983.tb00039.x.

DOI:10.1111/j.1365-2265.1983.tb00039.x
PMID:6416718
Abstract

Nine fertile women were treated with the luteinizing- hormone-releasing hormone agonist buserelin (seven women received 800 micrograms, two women 1200 micrograms intranasally for up to 24 weeks). Both doses produced sustained suppression of ovarian function, accompanied by hot flushes. In five women chemical castration was established within 1 to 5 weeks, whereas in the other four volunteers transient peaks of serum oestradiol occurred between the 6th and 19th weeks. Thereafter low postmenopausal oestradiol levels persisted. Chemical castration was confirmed by hormonal parameters and endometrial biopsies (inactive endometrium). After cessation of treatment normal cyclical function occurred immediately. This reversible chemical castration may be useful for new therapeutical approaches in sexual hormone dependent diseases (endometriosis, precocious puberty, metastatic breast cancer).

摘要

相似文献

1
Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
Clin Endocrinol (Oxf). 1983 Nov;19(5):613-7. doi: 10.1111/j.1365-2265.1983.tb00039.x.
2
Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.在间断经鼻给予促黄体生成素释放激素激动剂并联合孕激素诱导出血期间对排卵的抑制作用。
Fertil Steril. 1985 Jun;43(6):868-77. doi: 10.1016/s0015-0282(16)48614-0.
3
Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.使用促黄体生成素释放激素(LHRH)激动剂避孕:对促性腺激素和类固醇分泌模式的影响。
Clin Endocrinol (Oxf). 1984 Aug;21(2):179-88. doi: 10.1111/j.1365-2265.1984.tb03458.x.
4
Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.间歇性鼻内注射促黄体生成素释放激素激动剂联合口服孕激素作为抗排卵避孕方法的14天与21天方案
J Clin Endocrinol Metab. 1986 Dec;63(6):1379-85. doi: 10.1210/jcem-63-6-1379.
5
Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.布舍瑞林。对其药效学和药代动力学特性以及临床概况的综述。
Drugs. 1990 Mar;39(3):399-437. doi: 10.2165/00003495-199039030-00007.
6
Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.促黄体生成素释放激素(LH-RH)激动剂(布舍瑞林)诱导的可逆性性腺功能减退作为子宫内膜异位症的一种新治疗方法。
Fertil Steril. 1984 Jun;41(6):863-71. doi: 10.1016/s0015-0282(16)47899-4.
7
Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.服用含20微克炔雌醇的复方口服避孕药后血清促卵泡生成素、促黄体生成素、雌二醇-17β和孕酮的水平
Gynecol Obstet Invest. 1978;9(6):304-11. doi: 10.1159/000300999.
8
Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.接受慢性促黄体生成素释放激素激动剂治疗以避孕的女性的子宫内膜模式。
Fertil Steril. 1981 Sep;36(3):339-42. doi: 10.1016/s0015-0282(16)45735-3.
9
[Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].[促黄体生成素释放激素激动剂布舍瑞林在避孕应用中的进展:联合孕激素诱导撤退性出血的间歇用药]
Geburtshilfe Frauenheilkd. 1982 Dec;42(12):874-7. doi: 10.1055/s-2008-1037177.
10
Treatment with a luteinising-hormone-releasing-hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer.在绝经前转移性乳腺癌患者中使用促黄体生成素释放激素类似物(布舍瑞林)进行治疗。
Lancet. 1982 May 29;1(8283):1213-6. doi: 10.1016/s0140-6736(82)92339-x.

引用本文的文献

1
Breast cancer prevention through modulation of endogenous hormones.通过调节内源性激素预防乳腺癌。
Breast Cancer Res Treat. 1993 Nov;28(2):179-93. doi: 10.1007/BF00666430.
2
Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.布舍瑞林。对其药效学和药代动力学特性以及临床概况的综述。
Drugs. 1990 Mar;39(3):399-437. doi: 10.2165/00003495-199039030-00007.